Stock Price & Analysis

Buy GKOS stock as FDA acceptance of Epioxa and strong Q4 results position it well for growth. The stock's positive pre-market movement and analyst upgrades further support this decision.

Price Prediction for GKOS Stock in 2025

Based on current trends and upcoming catalysts, here is a concise price prediction for Glaukos Corp (GKOS):

1. Bullish Scenario: If FDA approves Epioxa by October 20, 2025, GKOS stock could reach $150 driven by strong revenue growth and market expansion in keratoconus treatment.

2. Bearish Scenario: Without FDA approval or significant delays, GKOS stock may drop to $80 due to reduced investor confidence and revenue growth concerns.

3. Current Price: GKOS stock is trading at $97.89 as of March 11, 2025, reflecting market anticipation of the FDA decision.

The S1 support level for GKOS Stock is $94.38 ,The R1 resistant level for GKOS Stock is $116.11.

As of the end of day on 2025-03-17, the price of GKOS Stock was $101.95.

The target price for GKOS Stock according to analyst rating is 163.80, with the highest price target at 200.00 and the lowest at 110.00. Analysts have a Strong Buy rating on GKOS Stock overall.

The market cap of GKOS is $5.8B.

GKOS may not be overvalued given its strong pipeline and upcoming catalysts. Valuation metrics like PE (18.46-20.62) and EV/EBITDA (10.74-11.04) align with growth expectations. Analysts maintain a positive outlook, with price targets up to $200. The FDA acceptance of Epioxa, a significant catalyst, could drive future growth. Current price ($97.89) is below analyst targets, suggesting potential upside.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

GKOS stock is projected to reach $250 by 2030, driven by its strong pipeline, including the potential FDA approval of Epioxa for keratoconus, and its expanding portfolio of innovative ophthalmic treatments. The company's focus on minimally invasive glaucoma therapies and its growing revenue from iDose products position it for sustained growth.

GKOS has a total of 907 employees.